Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evaxion Biotech ( (EVAX) ) has provided an announcement.
On January 7, 2026, Evaxion A/S announced that it will present its 2026 company milestones and provide a corporate update at the Biotech Showcase conference in San Francisco, held January 12-14, 2026. Chief executive Helen Tayton-Martin is scheduled to speak on January 13, 2026, with Evaxion also planning broader engagement with potential business partners and other stakeholders during the week, coinciding with the high-profile J.P. Morgan Healthcare Conference, which could enhance the company’s visibility and partnering prospects in the biotech and life sciences investment community.
The most recent analyst rating on (EVAX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by strong technical indicators and positive earnings call highlights, including a significant deal with MSD and promising clinical data. However, financial challenges such as persistent net losses and reliance on debt weigh down the score. The valuation remains unattractive due to a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Copenhagen-based, clinical-stage TechBio company that develops AI-Immunology-powered vaccines and novel immunotherapies. Using proprietary, scalable artificial intelligence models to decode the human immune system, the company is advancing a clinical-stage oncology pipeline of personalized cancer vaccines and a preclinical pipeline targeting bacterial and viral infectious diseases with high unmet medical need, positioning itself at the intersection of AI and immunotherapy.
Average Trading Volume: 285,077
Technical Sentiment Signal: Sell
Current Market Cap: $30.32M
See more data about EVAX stock on TipRanks’ Stock Analysis page.